The 3 Worst Drinks for Your Brain Health, According to Neurologists
"Our brain is an energy-intensive organ that relies on a steady supply of nutrients to function properly," explains , a cognitive-behavioral neurologist, chief medical officer of Isaac Health and a practitioner at NYU Langone Health. "What we eat and drink can influence brain function in both the short and long term."
Dr. Salinas says some beverages boast essential nutrients that support our brain health, while others might contribute to "inflammation, oxidative stress or changes in brain structure over time."
"By understanding these effects, we can make smarter choices to protect memory, focus, and overall brain function as we age," Dr. Salinas says.
Dr. Salinas and other neurologists revealed the three worst drinks for brain health and suggested what to sip (and do) instead.
Related:
Sorry to burst your bubble: While diet soda is sometimes billed as a "healthier" soda than regular sugary versions, research and neurologists caution it may not be the best choice for your brain.
"Numerous studies have indicated that aspartame may have a negative impact on brain health," warns , a neurologist and the vice chancellor at New York Medical College.
Dr. Etienne points to a 2017 cohort study published in Stroke that found that artificially sweetened soft drinks were linked with a higher risk of stroke and dementia. There was no significant increase in either one with sugar-sweetened beverages (which isn't to say those are boons for brain health either—see No. 2).
Dr. Salinas also mentioned the 2017 cohort study in Stroke.
"While this doesn't prove causation, it raises concerns that artificial sweeteners may impact brain function," Dr. Salinas says. "One possible explanation is that they could alter gut bacteria, which in turn, affects brain health, or that they might influence insulin responses, potentially impacting cognitive function."
Dr. Etienne said aspartame might also raise the levels of specific chemicals in the brain that can restrict the production of neurotransmitters like dopamine, norepinephrine and serotonin.
"These neurotransmitters play crucial roles in regulating neurophysiological activity," Dr. Etienne says. "Additionally, aspartame serves as a chemical stressor by raising plasma cortisol levels and promoting the production of excess free radicals."
Dr. Salinas notes we still need more research to clarify whether and why aspartame might have long-term risks for brain health.
Related:
Getting your fruit fix in liquid form may carry brain health risks if it's loaded with added sugars.
A 2023 study found that older adults who consumed the highest amounts of sugar were two times more likely to develop dementia than their peers with the lowest intake. Dr. Salinas points out that the study also specifically highlighted a link between fructose and sucrose, which are common in fruit juices, and a higher dementia risk.
"These findings suggest that excess sugar intake may contribute to brain aging and neurodegenerative diseases, possibly due to inflammation, insulin resistance and oxidative stress," Dr. Salinas says.
Dr. Etienne double-taps on the not-so-sweet issues with blood sugar.
"When sugar levels fluctuate rapidly, individuals may experience increased fatigue, difficulty concentrating and brain fog," Dr. Etienne says. "These symptoms can lead to irritability and mood swings."
Dr. Etienne says many of his patients returned to him and said their brain fog improved after reducing their sugar intake. Got a sweet tooth?
"Since the body does require some sugar, I recommend consuming whole fruits instead, as they provide natural sugars along with fiber, which promotes better gut health," Dr. Etienne says.
Related:
Moderate drinking, especially red wine, has historically been linked to better health outcomes. While some experts we spoke with did mention that a few studies suggest there's a chance moderate wine consumption might improve brain health, they don't recommend testing the theory. For starters?
"Let's be honest: Most people don't stop at just a glass a few times a week," says Jasdeep S. Hundal, Psy.D., ABPP-CN, the director of the Center for Memory & Healthy Aging at Hackensack Meridian Jersey Shore University Medical Center. "If you're drinking for the 'health benefits,' there are better ways to protect your brain."
There's also growing research warning of alcohol's impact on overall health, including cognitive.
A 2022 Natural Communications study of more than 36,000 people found that even one to two drinks daily can lower brain volume, especially in regions that affect cognition.
"These structural changes suggest that alcohol, even in small amounts, may not be as harmless as once thought," Dr. Salinas says.
Additionally, alcohol has immediate effects on your brain's capabilities.
"Wine consumption can cause immediate effects by disrupting neurotransmitter regulation and cause impaired thinking, sleep difficulties, migraines and coordination issues," warns Dr. Jasmin Dao, MD, Ph.D., a California-based pediatric and adult neurologist at Miller Children's & Women's Hospital Long Beach and MemorialCare Long Beach. "It can cause mood changes with increased feelings of depression, anxiety and anger."
Related:
Plain water bores you, and the above bums you out. We get it. The good news?
"There are many alternatives to sugary drinks," Dr. Dao says.
Dr. Dao recommends sipping these drinks for brain health:
Sparkling/bubbly water
Vegetable Juices
Water infused with natural flavorings, like fruit, vegetables and herbs
Coconut water
Green tea
Kombucha tea
What you eat is also essential.
"Eat a brain-healthy diet, like the Mediterranean or MIND diet," Dr. Salinas says. "These diets emphasize whole foods, healthy fats and antioxidants, which help reduce inflammation and support brain function."
A 2023 Neurology study suggests he's right.
Up Next:Dr. Joel Salinas, MD, MBA, MSc, FAAN, a cognitive-behavioral neurologist, chief medical officer of Isaac Health and a practitioner at NYU Langone Health
Dr. Mill Etienne, MD, MPH., FAAN, FAES, a neurologist and the vice chancellor at New York Medical College.
Jasdeep S. Hundal, Psy.D., ABPP-CN, the director of the Center for Memory & Healthy Aging at Hackensack Meridian Jersey Shore University Medical Center.
Dr. Jasmin Dao, MD, Ph.D., a California-based pediatric and adult neurologist at Miller Children's & Women's Hospital Long Beach and MemorialCare Long Beach
"Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology." Neurology.
"Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study." Stroke.
"Dietary Sugar Intake Associated with a Higher Risk of Dementia in Community-Dwelling Older Adults." Journal of Alzheimer's Disease.
"Moderate Wine Consumption and Health: A Narrative Review." Nutrients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
GLP-1 RAs Protective Against Stroke, Neurodegeneration?
TOPLINE: Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly semaglutide and tirzepatide, was associated with a 37% reduced risk for dementia and a 19% reduced risk for ischemic stroke in adults with type 2 diabetes (T2D) and obesity compared to the use of other antidiabetic drugs in a new retrospective cohort study. The neuroprotective effects of GLP-1 RAs were more pronounced in older adults, women, and those with a BMI of 30-40. METHODOLOGY: Investigators analyzed data on more than 60,000 adults aged 40 years or older with T2D and obesity and without type 1 diabetes or preexisting neurodegenerative or cerebrovascular diseases, obtained from electronic health records between 2017 and 2024. After propensity-score matching, participants receiving semaglutide or tirzepatide were assigned to the GLP-1 RA group (n = 30,430; mean age, 58 years; 50% women; 56% White individuals), and those receiving biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, and SGLT2 inhibitors were assigned to the 'other antidiabetic drug' group (n = 30,430; mean age, 58 years; 51% women; 56% White individuals). Primary outcomes were the incidence of new‐onset neurodegenerative diseases (dementia, Parkinson's disease, and mild cognitive impairment) and cerebrovascular diseases (ischemic stroke and intracerebral hemorrhage). The secondary outcome was all-cause mortality. TAKEAWAY: Patients taking GLP-1 RAs had a significantly lower risk for dementia (hazard ratio [HR], 0.63), ischemic stroke (HR, 0.81), and all-cause mortality (HR, 0.70) than those taking other antidiabetic drugs. Compared with use of other antidiabetic drugs, use of semaglutide was associated with reduced risk for dementia (HR, 0.63), whereas use of tirzepatide was associated with reduced risk for stroke (HR, 0.69) and all-cause mortality (HR, 0.48). No significant differences in risk for Parkinson's disease or intracerebral hemorrhage were observed between the GLP-1 RA group and the other antidiabetic group. The neuroprotective effects of GLP-1 RAs were more pronounced in women (HR, 0.85), adults aged 60 years or older (HR, 0.85), White individuals (HR, 0.86), and those with a BMI of 30-40 (HR, 0.82). IN PRACTICE: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with T2D and obesity,' the investigators wrote. 'If shown to be protective for neurodegenerative diseases in future trials, GLP-1 RAs could potentially be used clinically in disease prevention in the future,' Sarah Marzi, PhD, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, said in an online comment. Marzi was not involved with the current research. SOURCE: The study was led by Huan-Tang Lin, MD, PhD, Chang Gung Memorial Hospital, Taoyuan, Taiwan. It was published online on July 15 in JAMA Network Open. LIMITATIONS: As an observational study, residual confounding from unmeasured factors such as frailty or functional status could not be excluded, potentially introducing healthy user or selection bias. The database used lacked biomarker data, genetic profiles, and neuroimaging assessments, limiting further mechanistic interpretations. The analysis did not account for death as a competing risk. Additionally, medication exposure was inferred from prescriptions without confirmation of actual adherence or accurate drug doses. DISCLOSURES: The study was funded by the Ministry of Science and Technology, Taiwan, and the Chang Gung Memorial Hospital. The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Politico
18 hours ago
- Politico
3 things to know about Trump's vein condition
Here's what to know about the condition. How serious is it? CVI happens when leg veins are damaged and some blood cannot flow from the legs to the heart and pools up in the leg veins, causing swelling and other complications. The condition is generally mild but can worsen over time. If left untreated, it can cause a host of symptoms, including swelling, cramps, skin changes, leg ulcers, and varicose veins, which are veins that become swollen and twisted. 'What's interesting about this is that it runs the spectrum from very, very mild — where you might have a little bit of swelling, maybe a few varicose veins — to very severe, where you have very severe swelling, skin changes, hyperpigmentation, sort of fibrosis or leather appearance of the skin and even wounds,' said Dr. Thomas Maldonado, a vascular surgeon and medical director of the Venous Thromboembolic Center at NYU Langone Health. 'It's chronic, and over the course of a lifetime, especially as we age, this can be more severe.' Sean Barbabella, the president's physician, called CVI 'a benign and common condition, particularly in individuals over 70' in a letter released to the public. The condition can, however, be tied to more serious conditions, including deep vein thrombosis, a blood clot that forms in a deep vein, or pulmonary embolism, a blood clot that stops blood flow to an artery in the lung. Barbabella said Trump showed no signs of deep vein thrombosis or arterial disease. How common is it? CVI affects about 1 in 20 adults, according to the Cleveland Clinic . It's especially common in older adults, and the risk increases with age. Trump turned 79 last month. How is it treated? CVI has a handful of treatments, ranging from lifestyle changes to surgery. Barbabella, in his letter, did not specify what treatments — if any — Trump would be undergoing. Lifestyle changes, like regular exercise, leg elevation and weight management are usually the first steps to treating CVI, according to Maldonado. Compression therapy, which involves tight stockings or bandages, is also an option. Blood thinners are sometimes used to prevent blood clots from forming. Some treatments involve injecting a chemical into the veins, which causes scarring, so the veins no longer carry blood. For worse cases, surgery is sometimes necessary. That can involve tying off the problem vein so that it no longer transports blood, or, if necessary, removing the vein. Those options are usually only available if the vein is 'superficial,' or close to the skin. In cases where deeper veins are the ones damaged, surgery is usually not an option. 'Sometimes the ultrasound will show it's mostly in the deep system. And unfortunately, those are sacred. We can't really do surgery or shut those veins down. They're critical for the circulation,' said Maldonado. Maya Kaufman contributed to this report.
Yahoo
a day ago
- Yahoo
Stroke Diagnostic and Therapeutic Market to Hit Valuation of US$ 81.68 Billion By 2033
The stroke market is experiencing unprecedented growth, fueled by intense corporate investment and disruptive technologies like AI. This surge is rapidly advancing diagnostic speed and therapeutic options, fundamentally transforming the entire continuum of patient care. Chicago, July 17, 2025 (GLOBE NEWSWIRE) -- The global stroke diagnostic and therapeutic market was valued at US$ 42.07 billion in 2024 and is expected to reach US$ 81.68 billion by 2033, growing at a CAGR of 7.65% during the forecast period 2025–2033. Within the stroke diagnostic and therapeutic market, the segment for endovascular therapy (EVT) is experiencing unprecedented growth, solidified by a wave of compelling clinical evidence. A significant recent development involves a standardized, image-guided neurosurgical technique for clot removal in intracerebral hemorrhage, which has been shown to substantially improve patient outcomes; remarkably, the number needed to treat to achieve functional independence with this method is just eight patients. For ischemic stroke patients with large vessel occlusion and an extensive ischemic core, the benefits of EVT are now undisputed, with five randomized controlled trials confirming less disability compared to medical management alone. Request Sample Copy: The positive data is quantifiable, showing that for every 100 patients treated with EVT, an additional 17 achieve a better functional outcome and six more lives are saved. Further refining the treatment protocol, a post hoc analysis has revealed that administering intravenous thrombolysis (IVT) less than 140 minutes before EVT significantly boosts positive results. This efficacy extends to more distal blockages, as highlighted by a French registry on distal M2 MCA occlusions which reported successful reperfusion in 85% of patients undergoing EVT. The therapeutic landscape is also shifting, as five phase 3 trials have now established the noninferiority of tenecteplase when compared directly to alteplase, a change poised to significantly impact the stroke diagnostic and therapeutic market. Key Findings in Stroke Diagnostics and Therapeutics Market Market Forecast (2033) US$ 81.68 billion CAGR 7.65% Largest Region (2024) North America (29%) By Type Diagnostics (56.31%) By Application Ischemic Stroke (62.27%) Top Drivers Increasing global prevalence of stroke and associated risk factors Technological advancements in diagnostic imaging and minimally invasive therapies Rising healthcare expenditure and awareness of early stroke diagnosis Top Trends Growing adoption of artificial intelligence in stroke diagnosis Shift towards minimally invasive endovascular treatment procedures Expansion of telemedicine and remote tele-stroke services Top Challenges Stringent regulatory approvals for new devices and therapeutics Pharmaceutical Pipeline for Ischemic Stroke Explodes with Over 200 Novel Drugs The pharmaceutical pipeline is a highly competitive and lucrative corner of the stroke diagnostic and therapeutic market. The sheer scale of this research and development effort is immense, with over 50 companies actively working on more than 55 distinct pipeline drugs. In total, the current ischemic stroke pipeline features an impressive 202 drugs in various stages of development from 182 different companies and institutions, a testament to the vibrancy of the stroke diagnostic and therapeutic market. The preclinical stage is currently the most active area of innovation, with 76 unique drugs being investigated, signaling a robust future for novel therapies. Several candidates are progressing through the clinical trial process, generating significant market anticipation. Among them, JX10, a promising drug with both thrombolytic and anti-inflammatory properties, is currently in Phase II trials, while the neuroprotective agent Nelonemdaz has advanced to the critical Phase III stage. Adding to the momentum, an investigational drug known as AB126 is scheduled to commence a Phase I/II clinical trial in the first half of 2024. This wave of innovation is already impacting clinical practice, as highlighted by NICE's official recommendation in July 2024 to use tenecteplase for acute ischaemic stroke in adults. New Surgical and Drug Therapies Redefine Hemorrhagic Stroke Intervention Strategies Progress in managing hemorrhagic stroke is accelerating, creating new opportunities within the stroke diagnostic and therapeutic market. A landmark 2024 study has demonstrated for the first time the benefit of a standardized, image-guided microsurgical technique for clot removal over medical management alone, specifically leading to better six-month outcomes for patients with lobar hemorrhage. On the pharmaceutical front, for patients experiencing major intracranial bleeding related to Factor Xa inhibitors, the reversal agent andexanet alfa achieved hemostasis in a significant 67% of patients in a key trial. Another major advancement is seen in the treatment of subacute and chronic subdural hematoma, where middle meningeal artery embolization used as an adjunct to surgery drastically reduces the likelihood of recurrence. The recurrence rate within 90 days plummeted to just 4.1% in the group receiving embolization with surgery, compared to 11.3% in the surgery-only group. Alongside these interventions, research confirms that intensive blood pressure reduction in the initial stages of intracerebral hemorrhage effectively lessens the absolute growth of hematomas. Despite these gains, the precise role of surgery in hemorrhagic stroke continues to be a subject of intense research, shaping the future of the stroke diagnostic and therapeutic market. Telestroke Networks Emerge as a Critical Solution to Access-to-Care Gaps Telemedicine is proving to be an indispensable tool, expanding the reach of the stroke diagnostic and therapeutic market to underserved populations. The integration of telestroke platforms facilitates immediate remote consultations and allows for the continuous monitoring of patients, which is particularly crucial for improving care access in regions with limited specialized healthcare resources. The need for such systems is underscored by persistent gaps in public awareness; one survey revealed that only 38% of people could identify all major stroke symptoms and knew to call emergency services. This knowledge deficit contributes to treatment delays, as patients who arrive at an emergency room within three hours of their first symptoms often experience significantly less disability three months later. A nationwide study in the US highlighted the scale of this problem, finding that 54% of stroke patients arrived at a hospital more than two hours after their symptoms began, with these critical delays being more common among older, female, and Black patients. Telestroke networks directly address this challenge by providing a vital bridge, enabling rapid remote evaluation by neurologists to expedite life-saving treatment decisions. Technology-Infused Rehabilitation Creates New Pathways for Long-Term Stroke Recovery The field of stroke rehabilitation is being reinvented, representing a rapidly evolving segment of the stroke diagnostic and therapeutic market. Robotic devices are becoming central to this new paradigm, delivering the kind of highly targeted and intensive therapy needed to help patients regain critical motor function. A significant market development is the Vivistim Paired VNS System, a surgically implanted device that recently gained FDA approval for chronic stroke patients. This innovative vagus nerve stimulation system is specifically designed for individuals with moderate to severe upper arm impairment six months to over 20 years after their stroke. While the surgical procedure to implant the device has been established for decades, its application for stroke recovery is a novel and promising approach. Following implantation, patients engage in a rigorous six-week intensive rehabilitation program. This is complemented by the growing use of wearable technology, such as inertial measurement units and electromyography sensors, which allow for highly tailored assessments and therapies. Concurrently, home-based rehabilitation programs are gaining significant traction, offering patients a more convenient and cost-effective path to recovery. Advanced Neuroimaging Technologies Provide Unprecedented Clarity in Stroke Diagnosis The diagnostic imaging sector of the stroke diagnostic and therapeutic market is advancing rapidly, with new technologies providing unparalleled insights into the brain to facilitate earlier and more precise diagnoses. High-resolution magnetic resonance imaging (MRI) and computed tomography (CT) scans remain the cornerstones for the early detection and exact localization of stroke lesions. While non-contrast CT is still a primary modality for the initial evaluation of a suspected stroke, recent advances have boosted its overall diagnostic sensitivity to 64% and its specificity to 85%. A major technological leap occurred in December 2023 with the unveiling of the NAEOTOM Alpha, a pioneering diagnostic imaging system poised to set new standards in the field. Simultaneously, automated stroke detection software from leading companies like Brainomix, RapidAI, and is achieving widespread adoption and gaining significant market traction. The integration of artificial intelligence with this imaging data is a game-changer; it can now help clinicians predict the final infarct volume and accurately assess the risk of hemorrhagic transformation. Operator and Hospital Experience Emerge as Key Drivers of Patient Outcomes The correlation between procedural volume and patient outcomes is becoming a critical point of analysis for stakeholders in the stroke diagnostic and therapeutic market. A comprehensive study involving over 3,000 patients revealed a clear benefit associated with experienced clinicians; it found that higher proceduralist volume, defined as performing 18 or more endovascular therapies per year, was directly associated with reduced in-hospital mortality. The data showed that the absolute risk of death was 4.8% lower in this high-volume group. Another study, however, observed a paradoxical relationship where higher-volume hospitals had worse outcomes, a finding likely attributable to these centers treating a greater proportion of severe and complex cases. This was supported by an analysis where the odds of in-hospital mortality actually increased in higher-volume quartiles. A snapshot from Florida in 2019 showed that of the 297 hospitals, 105 performed mechanical thrombectomy. Among these, 54 were classified as high-volume centers (≥15 MTs/year), with a median of 59.5 cases, compared to a median of just two cases at low-volume hospitals. Stroke's Staggering Global Impact Drives Demand for Innovative Care Solutions Stroke persists as a formidable global health crisis, which in turn fuels the immense global stroke diagnostic and therapeutic market. In 2021 alone, there were 93.8 million stroke survivors and 11.9 million new cases, highlighting the immense scale of the issue. The global cost of stroke is now estimated to be over US$890 billion, placing an enormous economic burden on healthcare systems. Ischemic stroke was the predominant type, accounting for 65.3% of all new strokes in 2021, with a slightly higher incidence among males (52.6%). There are significant regional disparities in both incidence and mortality, revealing inequities in access to care. The lowest age-standardized stroke incidence was observed in Luxembourg (57.7 per 100,000), while the Solomon Islands faced the highest rate (355.0 per 100,000). Similarly, Singapore reported the lowest stroke death rate at 14.2 per 100,000, which stands in stark contrast to North Macedonia, the country with the highest mortality rate at 277.4 per 100,000, illustrating the urgent need for globally accessible and effective solutions from the stroke diagnostic and therapeutic market. Tailor This Report to Your Specific Business Needs: Expanding Therapeutic Windows for Intervention Offer Hope for More Patients Recent clinical research is fundamentally challenging and expanding the traditionally accepted timeframes for effective stroke intervention, a development with profound implications for the stroke diagnostic and therapeutic market. The CT for Late Endovascular Reperfusion (CLEAR) study, which enrolled 2,451 patients, was designed specifically to assess the benefits of EVT within an extended time window, suggesting that even patients with a large ischemic core may still benefit. This is reinforced by a propensity score-matched analysis which found that approximately one-third of large vessel occlusion patients with persistent deficits beyond the 16-hour mark still met the stringent criteria for late-window trials like DAWN or DEFUSE 3. When EVT was performed in these late-presenting patients, it resulted in 11.08-fold higher odds of achieving a good functional outcome. These findings add urgency to the treatment process, as demonstrated by foundational studies like MR CLEAN, which showed that every single hour of delay in achieving reperfusion led to a 7.7% decreased probability of the patient regaining functional independence. Likewise, the REVASCAT trial quantified the cost of delay, showing a 26% decrease in the likelihood of a favorable outcome for every 30-minute delay in reperfusion. Top Companies in Stroke Diagnostic and Therapeutic Market Abbott Laboratories Boston Scientific Corporation Cerebrotech Medical Systems, Inc. Cordis Corporation GE Healthcare Genentech Inc. Gowerlabs Hyperfine MRI Koninklijke Philips N.V. Medfield Diagnostics Medtronic plc. Merck & Co., Inc. Neural Analytics NIRX Samsung Neurologica Siemens AG Stryker Corporation Other Prominent Players Market Segmentation Overview By Type Diagnostics Magnetic Resonance Imaging (MRI) Computed Tomography Scan (CT scan) Electrocardiography Carotid Ultrasound Cerebral Angiography Others Therapeutics Tissue Plasminogen Activator Antiplatelet Antihypertensive Anticoagulant By Application Hemorrhagic Stroke Ischemic Stroke By Region North America Europe Asia Pacific Middle East Africa South America Want Deeper Insights? Book a Free Call with an Expert: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
